SMS Pharma Gets EIR for Hyderabad API Facility
ECONOMY & POLICY

SMS Pharma Gets EIR for Hyderabad API Facility

SMS Pharmaceuticals Limited announced the receipt of the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredient (API) facility at Bachupally, Hyderabad. The inspection was conducted between 17th and 21st March 2025.

The inspection concluded with one procedural observation on Form 483, which has already been addressed by the company. The issuance of the EIR marks the formal closure of the audit.

The Hyderabad unit has a manufacturing capacity of 120 kilolitres and specialises in niche, small-volume, high-value molecules. It holds multiple global regulatory approvals including those from USFDA, European Union Good Manufacturing Practice (EU GMP), Korea Food and Drug Administration (KFDA), Brazilian Health Regulatory Agency (ANVISA), Pharmaceuticals and Medical Devices Agency (PMDA), and Central Drugs Standard Control Organisation (CDSCO).

Established in 1990, SMS Pharma serves global clients across over seventy countries, with facilities in Hyderabad and Vizag. The company is supported by in-house research and development capabilities and operates in a wide range of therapeutic categories.

Source:
SMS Pharmaceuticals Limited 

SMS Pharmaceuticals Limited announced the receipt of the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredient (API) facility at Bachupally, Hyderabad. The inspection was conducted between 17th and 21st March 2025. The inspection concluded with one procedural observation on Form 483, which has already been addressed by the company. The issuance of the EIR marks the formal closure of the audit. The Hyderabad unit has a manufacturing capacity of 120 kilolitres and specialises in niche, small-volume, high-value molecules. It holds multiple global regulatory approvals including those from USFDA, European Union Good Manufacturing Practice (EU GMP), Korea Food and Drug Administration (KFDA), Brazilian Health Regulatory Agency (ANVISA), Pharmaceuticals and Medical Devices Agency (PMDA), and Central Drugs Standard Control Organisation (CDSCO). Established in 1990, SMS Pharma serves global clients across over seventy countries, with facilities in Hyderabad and Vizag. The company is supported by in-house research and development capabilities and operates in a wide range of therapeutic categories. Source: SMS Pharmaceuticals Limited 

Next Story
Infrastructure Urban

ISRO’s IMAT Success Boosts Readiness for Maiden Gaganyaan Mission

Union Minister of State for Science and Technology Dr Jitendra Singh informed Parliament that ISRO has achieved a key milestone in its preparations for India’s first human space mission with the successful completion of the Integrated Main Parachute Airdrop Test (IMAT). He said in the Lok Sabha that the test forms a central part of the qualification campaign for the Crew Module’s parachute-based deceleration system, one of the most vital elements in human-rating the mission.According to Dr. Jitendra Singh, the IMAT recreated one of the most demanding descent conditions by intentionally del..

Next Story
Infrastructure Urban

Gyanesh Kumar Takes Charge as Chair of International IDEA Council

Chief Election Commissioner of India Gyanesh Kumar has assumed the Chairship of the Council of Member States of the International Institute for Democracy and Electoral Assistance for 2026. The ceremony in Stockholm was also attended by India’s Ambassador to Sweden, Anurag Bhushan. India, a founding member of International IDEA, has long contributed to the organisation’s governance and global democratic dialogue, and the new Chairship signals broad recognition of the Election Commission of India as a trusted and innovative election management institution.During his visit, Kumar held discuss..

Next Story
Infrastructure Energy

Coal Mines Boost Local Growth and Support India’s Energy Self-reliance

The Magadh and Amrapali coal mines in Jharkhand are playing a pivotal role in strengthening India’s energy security, contributing nearly half of Central Coalfields Limited’s total coal production in 2024–25. Both mines support the broader goal of ensuring steady coal availability for the power sector under the vision of Aatmanirbhar Bharat. Magadh has estimated mineable reserves of 854.91 million tonnes, while Amrapali holds 456.34 million tonne. For FY 2025–26, the two are expected to generate net sales revenues of Rs 28.12 billion and Rs 23.67 billion respectively. Local development ..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Advertisement

Get CW App